Market news

Benjamin Hohl, CFO, on September 17, 2026, sold 6,018 shares in Enliven Therapeutics (ELVN) for $303

Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.

Enliven Therapeutics (ELVN) has an average rating of buy and mean price target of $73.45, according

Enliven Therapeutics (ELVN) has an average rating of buy and mean price target of $73.45, according

Enliven Therapeutics (ELVN) has an average rating of buy and mean price target of $73.45, according

Detailed price information for Amn Healthcare Services Inc (AMN-N) from The Globe and Mail including charting and trades.

Detailed price information for Geron Corp (GERN-Q) from The Globe and Mail including charting and trades.

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Helen Louise Collins, Chief Medical Officer, on July 17, 2026, sold 5,000 shares in Enliven Therapeu

Benjamin Hohl, CFO, on July 17, 2026, sold 6,018 shares in Enliven Therapeutics (ELVN) for $316,780.

Enliven Therapeutics has raced ahead with a 220.6% year to date return, yet the broader valuation checks and market multiples now lean toward the stock looking expensive rather than like an obvious bargain. The year to date gain of 220.6% suggests expectations around Enliven Therapeutics have reset significantly higher and leaves less room for disappointment. Upcoming work on the ENABLE-2 Phase 3 trial for ELVN-001 can support long term value if progress continues as planned, while recent...